thromboxane-b2 and Migraine-Disorders

We investigated the biological and clinical effects of naproxen sodium (NxS) in the short-term prophylaxis of pure menstrual migraine (PMM) in 25 women suffering from migraine without aura, occurring exclusively from 2 days before to 5 days after menstruation onset. Daily oral NxS (550 mg) from 7 days before menstruation to 7 days after menstruation onset was given for 3 menstrual cycles, and 5 days before menstruation to 5 days after menstruation onset over the next 3 menstrual cycles. In the month before initiation of treatment and in the third month of treatment, 6-keto-PGF1(alpha), TXB(2) and PGE(2) were measured in plasma before menstruation (day -2) and on the second day (day +2) after bleeding onset. In the 20 women analysed, 6-keto-PGF1(alpha) was 17% lower (p<0.0001) and TXB(2) was 30% lower (p<0.0001) on day -2 during treatment than the same day pretreatment; TXB(2) was also lower (p<0.02) on day +2 during treatment than day +2 pretreatment. The 6-keto-PGF1(alpha)/TXB(2) ratio was higher (p<0.01) on day -2 treatment than day -2 pretreatment. PGE(2) levels were significantly lower (p<0.002) on day +2 than pre-treatment values on the same day. The number of attacks reduced from 1.7+/-0.11 pretreatment to 1.2+/-0.10 at the 3rd month (p<0.001), to 1.1+/-0.06 at the 6th month (p<0.0001). The duration reduced from 25.6+/-4.42 h pretreatment to 15.5+/-4.43 h in the 3rd month (p<0.02), to 13.35+/-4.26 h in the 6th month (p<0.001). The intensity reduced from 2.4+/-0.11 pretreatment, to 1.2+/-0.10 in the 3rd month of treatment (p<0.0001), and 1.1+/-0.07 in the 6th month (p<0.0001).

Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Adult; Cyclooxygenase Inhibitors; Dinoprostone; Down-Regulation; Drug Administration Schedule; Female; Humans; Menstruation Disturbances; Middle Aged; Migraine Disorders; Naproxen; Predictive Value of Tests; Thromboxane B2; Time Factors; Treatment Outcome

Morphological and functional alterations of platelets in migraineurs may be linked to the development of migraine. We examined the eicosanoid synthesis of platelets of untreated female migraineurs in a headache-free period and compared it to that of age- and blood group-matched healthy female volunteers. In the platelets of headache-free migraineurs significantly less amounts of anti-aggregatory prostaglandin D2 and prostacyclin, as well as of 12-L-hydroxy-5,8,10-heptadecatrienoic acid (a potent endogenous inducer of endothelial prostacyclin production) were produced, while the synthesis of platelet aggregatory thromboxane did not differ when compared to that of healthy women. These results suggest that the platelet eicosanoids of migraineurs in the headache-free period might promote the development of cellular, vascular and neurological events inducing headache.

Topics: Adult; Arachidonic Acid; Blood Platelets; Case-Control Studies; Eicosanoids; Epoprostenol; Fatty Acids, Unsaturated; Female; Humans; Lipoxygenase; Middle Aged; Migraine Disorders; Prostaglandin D2; Prostaglandin-Endoperoxide Synthases; Thromboxane B2

We analysed 22 patients suffering from migraine to evaluate the possible activation of platelet function utilizing the following methods: platelet factor 4, thromboxane B2 and 6 - keto prostaglandin F 1 alpha levels in platelet poor plasma. Laboratory tests were performed on all patients during headache-free period and the results obtained were compared with those of a normal healthy individuals. The mean results obtained in the patients group during pain-free period indicated a significant activation of platelet function when compared with the normal group.

Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Platelet Factor 4; Thromboxane B2

Several disturbances in platelet function have been reported in migraine and tension-type headache (TH). The plasma 11-dehydrothromboxane B2 (11-dTXB2) is free from artifactual increase during blood sampling, and it can be a reliable indicator of thromboxane A2 (TXA2) production in vivo. TXA2 is a very potent proaggregatory and vasoconstrictory metabolite formed in the platelets. We investigated plasma 11-dTXB2 and 5-hydroxytryptamine (5-HT) levels in patients with migraine during headache-free periods and in patients with chronic TH. The mean value of plasma 11-dTXB2 levels in migrainous patients was significantly higher than those in TH patients and healthy controls. The mean value of plasma 5-HT levels in TH patients was significantly lower than those in migrainous patients and healthy controls. There was no correlation between plasma 11-dTXB2 levels and plasma 5-HT levels in any group. The results suggest the existence of continuous platelet activation in migrainous patients.

Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Platelet Activation; Serotonin; Tension-Type Headache; Thromboxane B2

Eighteen patients suffering from true menstrual migraine and 12 control subjects were studied. We evaluated in different phases of the menstrual cycle and during the migraine crisis the peripheral plasma concentrations of 6-keto-PGF1 alpha (the stable metabolite of PGI2), thromboxane B2 (the stable metabolite of thromboxane A2), PGF2 alpha and PGE2. The mean values of 6-keto-PGF1 alpha in menstrual migraine sufferers are lower than in normal women throughout the whole cycle. The difference between the trends observed in the two groups is statistically significant (p less than 0.05). The plasma levels of TXB2 and of PGF2 alpha are similar in the two groups investigated, both in basal conditions and during the attack. The plasma concentrations of PGE2 are slightly lower in migraineurs in basal conditions than in normals. However, during the crisis they increase significantly (p less than 0.05). In conclusion, among all the parameters considered, PGE2 seems to play the most important role during the pain phase of the attack. The results of the present study suggest that a deficit of PGI2, one of the most important protecting agents against ischemia, might be a typical feature of menstrual migraine and might cause in these patients a vascular hypersensitivity to different ischemic stimuli.

Topics: 6-Ketoprostaglandin F1 alpha; Adult; Dinoprostone; Female; Humans; Menstrual Cycle; Migraine Disorders; Thromboxane B2

It has been reported that migraine sufferers have an enhanced platelet activity, as well as an enhanced thromboembolic risk. In this study, 12 subjects with classic migraine were compared with 12 age- and sex-matched controls. The following parameters were tested: platelet aggregation; platelet content of ADP, ATP and cyclic-AMP (cAMP); plasma levels of cAMP, 6-keto-PGF1 alpha and thromboxane B2, serum levels of TxB2 and lipids. ADP- and adrenaline-induced platelet aggregation, platelet content of ADP, ATP and cAMP did not differ significantly between the groups. Platelets from migraine subjects, however, showed a decreased beta-adrenoceptor response to stimulation with isoprenaline when determined as platelet cAMP production in vitro. The prostacyclin metabolite 6-keto-PGF 1 alpha was significantly decreased in the migraine group. No difference were observed in TxB2. Plasma lipids were similar, except that the migraine cases had higher levels of LDL-cholesterol. These data do not confirm a general platelet malfunction in migraine patients, but suggest a decreased functional capacity of platelet beta-adrenoceptors and an altered metabolism of prostacyclin and LDL-cholesterol.

Topics: 6-Ketoprostaglandin F1 alpha; Adult; Blood Platelets; Cholesterol, LDL; Cyclic AMP; Female; Humans; Male; Middle Aged; Migraine Disorders; Platelet Aggregation; Receptors, Adrenergic, beta; Thromboxane B2

Topics: Adolescent; beta-Thromboglobulin; Child; Erythrocyte Aggregation; Female; Humans; Male; Migraine Disorders; Platelet Factor 4; Thromboxane B2

Topics: 6-Ketoprostaglandin F1 alpha; Blood Platelets; Epoprostenol; Female; Humans; Menstrual Cycle; Migraine Disorders; Platelet Aggregation; Serotonin; Thromboxane B2

Alterations in platelet function and other hemorheologic factors have been reported to occur in patients with migraine. The prophylactic treatment of migraine with beta blockers is at present well established, and non-selective as well as beta 1-selective beta blockers exert an effect. The aim of this presentation is to summarize how beta blockers, depending on their receptor selectivity, modulate platelet function and hemorheologic factors. We conclude that non-selective beta blockade increases factors, such as platelet aggregability, and decreases fibrinolytic activity compared with beta 1-selective blockade with metoprolol. These differences do not reflect on their migraine prophylactic effect and indicate that alterations in platelet function are not a primary cause of migraine: rather, they are epiphenomena.

Topics: 6-Ketoprostaglandin F1 alpha; Adrenergic beta-Antagonists; Erythrocytes; Fibrinolysis; Humans; Lipoproteins; Metoprolol; Migraine Disorders; Platelet Aggregation; Propranolol; Rheology; Thromboxane B2

Topics: Adolescent; Adult; Age Factors; Blood Platelets; Child; Child, Preschool; Humans; Middle Aged; Migraine Disorders; Thromboxane A2; Thromboxane B2; Thromboxanes